Pablo Lapuerta

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Topics

Combination Therapy

Top Venues

Clinical pharmacology and therapeutics

Cancer management and research

This page only lists publications with an associated author ORCID identifier.

Publications

Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle, Chenghai Li, Tong Li, Helen Wang, Marcus Hompesch
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin. Clinical pharmacology and therapeutics (2024)
Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle, Chenghai Li, Tong Li, Helen Wang, Marcus Hompesch
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin. Clinical pharmacology and therapeutics 115 (6) (2024)
Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle, Chenghai Li, Tong Li, Helen Wang, Marcus Hompesch
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin. Clinical pharmacology and therapeutics 115 (6) (2024)
David C Metz, Eric Liu, Vijay N Joish, Lynn Huynh, Todor I Totev, Mei Sheng Duh, Kiernan Seth, Susan Giacalone, Pablo Lapuerta, Michael A Morse
Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome. Cancer management and research 12 (2020)